Drug Interactions between HDL Benefit and pitavastatin
This report displays the potential drug interactions for the following 2 drugs:
- HDL Benefit (niacin)
- pitavastatin
Interactions between your drugs
niacin pitavastatin
Applies to: HDL Benefit (niacin) and pitavastatin
ADJUST DOSE: Severe myopathy and rhabdomyolysis have been reported with concomitant use of HMG-CoA reductase inhibitors (i.e., statins) and niacin. The mechanism is unknown; however, the development of myopathy has been associated with both the administration of statins alone and lipid-modifying dosages of niacin (1 g/day or more) alone. Certain populations may be more susceptible to the interaction. In a double-blind, randomized cardiovascular outcomes trial for simvastatin, the incidence of myopathy was found to be higher in patients of Chinese descent (0.43%) compared to patients not of Chinese descent (0.03%) taking 40 mg simvastatin and lipid-modifying dosages of a niacin-containing product. The cause of the increased risk is unknown, and it is also unknown if the increased risk applies to other Asian populations or to other statins when given to Chinese patients.
MANAGEMENT: Concomitant use of statins with lipid-modifying dosages of niacin (1 g/day or more) should be approached cautiously and only if the benefit of further alterations in lipid levels is anticipated to outweigh the potential risks. Addition of niacin to statin therapy typically provides little additional reduction in LDL cholesterol, but further reductions of triglycerides and increases in HDL cholesterol may be attained. If the combination is prescribed, lower dosages of the statin should be considered. Coadministration of simvastatin with high doses of niacin (1 g/day or more) is not recommended in Chinese patients due to an increased risk of myopathy. Lovastatin labeling recommends that the dosage not exceed 20 mg daily when prescribed with lipid-modifying dosages of niacin. All patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.
References (12)
- Mauro VF (1993) "Clinical pharmacokinetics and practical applications of simvastatin." Clin Pharmacokinet, 24, p. 195-202
- Mauro VF, MacDonald JL (1991) "Simvastatin: a review of its pharmacology and clinical use." DICP, 25, p. 257-64
- Reaven P, Witztum JL (1988) "Lovastatin, nicotinic acid, and rhabdomyolysis." Ann Intern Med, 109, p. 597-8
- Norman DJ, Illingworth DR, Munson J, Hosenpud J (1988) "Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin." N Engl J Med, 318, p. 46-7
- Malloy MJ, Kane JP, Kunitake ST, Tun P (1987) "Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia." Ann Intern Med, 107, p. 616-23
- (2002) "Product Information. Mevacor (lovastatin)." Merck & Co., Inc
- (2001) "Product Information. Zocor (simvastatin)." Merck & Co., Inc
- (2001) "Product Information. Lipitor (atorvastatin)." Parke-Davis
- (2001) "Product Information. Baycol (cerivastatin)." Bayer
- (2003) "Product Information. Crestor (rosuvastatin)." AstraZeneca Pharma Inc
- (2004) "Product Information. Vytorin (ezetimibe-simvastatin)." Merck & Co., Inc
- FDA. U.S. Food and Drug Administration (2010) FDA drug safety communication: Ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm204882.htm
Drug and food interactions
niacin food
Applies to: HDL Benefit (niacin)
GENERALLY AVOID: Ethanol can exacerbate the cutaneous flushing that is a common side effect of niacin. At least one case of delirium and lactic acidosis has been reported with coadministration of these drugs, although data are limited.
MANAGEMENT: Coadministration should probably be discouraged, particularly since chronic consumption of large amounts of alcohol is associated with hyperlipidemia.
References (1)
- Schwab RA, Bachhuber BH (1991) "Delirium and lactic acidosis caused by ethanol and niacin coingestion." Am J Emerg Med, 9, p. 363-5
niacin food
Applies to: HDL Benefit (niacin)
A single case has been reported in which cutaneous flushing and tremors were noted in a woman who was taking niacin while wearing a nicotine patch. The mechanism is suspected to be synergistic cutaneous vasodilatory effects. The clinical significance of this possible interaction is not known.
References (1)
- Rockwell KA Jr (1993) "Potential interaction between niacin and transdermal nicotine." Ann Pharmacother, 27, p. 1283-8
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.